277 материалов по теме, собраны автоматически из проверенных источников
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial The Manila Times
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial GlobeNewswire
Health Rounds: New dye for MRI exams detects lung cancer earlier WTVB
Health Rounds: New dye for MRI exams detects lung cancer earlier WKZO
Wang Jie: Chinese research is reshaping the global fight against lung cancer People's Daily Online
In the SWOG S1827 MAVERICK Phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure-free survival (the primary endpoint of the trial), without an apparent difference in…
Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association…
A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding–based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to…
New research expands treatment options for small cell lung cancer wbbjtv.com
Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World…
Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial MedPage Today
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart, compared with 10.0 months for patients receiving docetaxel, according to…
Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented at the International Association for the…
Новый препарат остановил метастатический рак легких у 94% пациентов hightech.plus
Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.